Metabolomic profiling to find blood markers for severe traumatic brain injury
Metabolomic Profiling of Patients With Traumatic Brain Injury
This project will test whether patterns of small molecules in the blood can distinguish adults with severe TBI from injured patients without brain injury.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Academic / other |
| Locations | 1 site (Aksaray, Ankara) |
| Trial ID | NCT07292766 on ClinicalTrials.gov |
What this trial studies
This is an observational study that compares blood metabolite levels between adults with clinically defined severe TBI and orthopedic or multitrauma patients without brain injury. Researchers will use metabolomic techniques to measure small molecules (under 500 Da) in systemic circulation to look for signatures related to energy failure and blood–brain barrier dysfunction after TBI. The goal is to identify metabolites that correlate with injury severity or prognosis rather than to test a therapy. Enrollment is for adults aged 18–65 and the work is conducted at a single tertiary hospital in Ankara, Turkey.
Who should consider this trial
Good fit: Ideal candidates are adults 18–65 with clinically or imaging-confirmed severe TBI, and the study also includes orthopedic/multitrauma patients without brain injury as comparison subjects, excluding those with preexisting brain pathology or chronic subdural hematoma.
Not a fit: Patients outside the 18–65 age range, those with preexisting brain disease or chronic subdural hematoma, or anyone hoping for a direct therapeutic effect will not benefit because this is observational biomarker research.
Why it matters
Potential benefit: If successful, the findings could provide blood-based markers to help doctors estimate injury severity and guide monitoring or treatment decisions.
How similar studies have performed: Metabolomic profiling in TBI is an emerging field with preliminary studies showing distinct metabolic changes, but findings are not yet established for routine clinical use.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 18-65 * Patients diagnosed with severe TBI clinically or according to National Institute for Health and Care Excellence (NICE) criteria (including post-traumatic imaging) * Patients with non-TBI orthopedic or multitrauma Exclusion Criteria: * Presence of brain pathology in the pre-trauma period * Patient with chronic subdural hematoma
Where this trial is running
Aksaray, Ankara
- Aksaray University — Aksaray, Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Hazal Ekin AYTUĞ, Consultant anesthesiologist
- Email: drekinguran@gmail.com
- Phone: +905078448449
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.